We are live on
!
Find out more
BM
Bridger Management Portfolio holdings
AUM
$128M
1-Year Est. Return
9.54%
This Fund
S&P 500
This Quarter
Est. Return
+9.09%
1 Year Est. Return
+9.54%
3 Year Est. Return
+98.31%
5 Year Est. Return
+125.76%
10 Year Est. Return
+911.97%
AUM
$1.85B
AUM Growth
+$197M
(+12%)
Cap. Flow
+$123M
Cap. Flow
% of AUM
6.68%
Top 10 Holdings %
Top 10 Hldgs %
44.72%
Holding
42
New
5
Increased
15
Reduced
7
Closed
5
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
HCA Healthcare
HCA
|
+$88.9M |
| 2 |
Amneal Pharmaceuticals
AMRX
|
+$37.6M |
| 3 |
Nektar Therapeutics
NKTR
|
+$35.8M |
| 4 |
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
|
+$25.1M |
| 5 |
Heron Therapeutics
HRTX
|
+$22.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Incyte
INCY
|
+$51.8M |
| 2 |
Labcorp
LH
|
+$48.1M |
| 3 |
Bank of America
BAC
|
+$28.3M |
| 4 |
DexCom
DXCM
|
+$19.2M |
| 5 |
Humana
HUM
|
+$12.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 46.5% |
| 2 | Consumer Discretionary | 11.23% |
| 3 | Technology | 8.75% |
| 4 | Communication Services | 8.56% |
| 5 | Consumer Staples | 5.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Rocket Pharmaceuticals
RCKT
$341M
| $34.4M | 1.86% |
1,752,902
+174,333
| +11% | +$3.3M |
|
|
MSGN
27
DELISTED
MSG Networks Inc.
MSGN
| $32.2M | 1.75% |
1,346,056
| – | – |
|
28
ScottsMiracle-Gro
SMG
$3.89B
| $30.7M | 1.66% |
369,057
+25,783
| +8% | +$2.16M |
|
29
Liberty Broadband Class A
LBRDA
$4.91B
| $29.5M | 1.6% |
390,292
| – | – |
|
30
TG Therapeutics
TGTX
$7.97B
| $28.8M | 1.56% |
2,190,085
-183,835
| -8% | -$2.53M |
|
|
GDEN
31
DELISTED
Golden Entertainment
GDEN
| $24.3M | 1.32% |
901,443
+138,873
| +18% | +$3.88M |
|
32
Shake Shack
SHAK
$2.51B
| $23.2M | 1.26% |
+350,804
| New | +$19.4M |
|
33
Wave Life Sciences
WVE
$1.1B
| $21.5M | 1.17% |
562,615
+43,180
| +8% | +$1.86M |
|
34
VeriSign
VRSN
$26.4B
| $18.3M | 0.99% |
133,456
| – | – |
|
|
PVG
35
DELISTED
PRETIUM RESOURCES INC.
PVG
| $12.1M | 0.66% |
1,651,328
| – | – |
|
|
CSII
36
DELISTED
Cardiovascular Systems, Inc.
CSII
| $11.4M | 0.62% |
+352,783
| New | +$9.71M |
|
37
GrafTech
EAF
$175M
| $5.39M | 0.29% |
+29,980
| New | +$5.47M |
|
|
38
Bank of America
BAC
$436B
| – | – |
-942,436
| Closed | -$28.3M |
|
39
Denali Therapeutics
DNLI
$3.69B
| – | – |
-312,500
| Closed | -$5.05M |
|
|
40
Incyte
INCY
$24.4B
| – | – |
-622,152
| Closed | -$51.8M |
|
|
ALXN
41
DELISTED
Alexion Pharmaceuticals
ALXN
| – | – |
-92,074
| Closed | -$10.3M |
|
|
ARMO
42
DELISTED
ARMO BioSciences, Inc. Common Stock
ARMO
| – | – |
-232,115
| Closed | -$8.68M |
|
Similar funds
SHFC
IUC
PC
SIM
PIA
S
CF
BC
Bridger Management's Q2 2018 Portfolio in Review
As of Q2 2018, Bridger Management held 42 positions worth $1.85B, up 12% from $1.65B the previous quarter. Its ten largest holdings account for 45% of the portfolio.
Bridger Management deployed $123M of net new capital in Q2 2018, opening 5 new positions and adding to 15 existing holdings. Its largest new stake was HCA Healthcare: 878,761 shares worth $90.2M.
By sector, the portfolio is most concentrated in Healthcare at 46% of assets, down from 48% a quarter earlier, followed by Consumer Discretionary and Technology.
On the sell side, the largest reduction was Labcorp, an estimated $48.1M trimmed.
- Bridger Management's largest Q2 2018 buy was HCA Healthcare: 878,761 shares worth $90.2M.
- Bridger Management added most to Nektar Therapeutics in Q2 2018, an estimated $35.8M increase.
- Bridger Management's biggest Q2 2018 reduction was Labcorp, cutting an estimated $48.1M.
- Bridger Management fully exited Incyte in Q2 2018, selling an estimated $51.8M.
- Bridger Management's ten largest holdings make up 45% of its $1.85B portfolio in Q2 2018.
- Bridger Management opened 5 new positions and closed 5 in Q2 2018.
- Bridger Management's portfolio value rose 12% quarter-over-quarter to $1.85B.
Based on Bridger Management's 13F filing for Q2 2018, filed 14 Aug 2018.